The proposed acquisition consideration represents an equity value of $2.4 billion and an enterprise value of $2.5 billion, Sumitovant Biopharma said in a statement.
(Reporting by Anirudh Saligrama in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
300 JPY | -0.66% | -10.71% | -35.62% |
05-09 | Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd. | CI |
05-07 | Profit-Taking, China Outlooks Churn Asian Stock Markets | MT |
(Reuters) - Sumitovant Biopharma said on Sunday the company and its parent Sumitomo Pharma Co Ltd had submitted a non-binding offer to acquire Myovant Sciences Ltd.
The proposed acquisition consideration represents an equity value of $2.4 billion and an enterprise value of $2.5 billion, Sumitovant Biopharma said in a statement.
(Reporting by Anirudh Saligrama in Bengaluru)
1st Jan change | Capi. | |
---|---|---|
-35.62% | 764M | |
+38.69% | 728B | |
+33.18% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+16.04% | 244B | |
+7.71% | 207B | |
-5.56% | 205B | |
-0.35% | 163B |